T. Rowe Price Investment Management, Inc.

Position in ERAS — Erasca, Inc.

CIK 1897612 BALTIMORE, MD

Position in ERAS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$343,981,072

+$284,046,612 QoQ

Shares Held

21,259,646

+32.0% QoQ

Ownership

6.84%

of shares outstanding

% of Portfolio

0.24%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2024

8 quarters on record

Voting authority Sole 96.43909404700341.ToString("F0")% Shared 0.ToString("F0")% None 3.5609059529965834.ToString("F0")%

Healthcare · as of Mar 31, 2026

T. Rowe Price Investment Management, Inc. holds $11,176,949,825 across 48 Biotechnology names. ERAS ranks #12 (3.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	5,193,324	$1,718,315,111
2	ASND	Ascendis Pharma A/S	6,162,042	$1,409,443,866
3	CYTK	Cytokinetics Inc	17,523,840	$1,154,996,294
4	APGE	Apogee Therapeutics, Inc.	10,300,984	$867,033,823
5	PCVX	Vaxcyte, Inc.	12,126,017	$704,642,847
6	DYN	Dyne Therapeutics, Inc.	30,785,801	$558,146,572
7	BNTX	BioNTech SE	5,856,073	$520,487,768
8	IONS	Ionis Pharmaceuticals Inc	6,159,027	$462,481,337

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$343,981,072	21,259,646	+32.0%	Shares	Sole	2026-05-15
2025-12-31	$59,934,460	16,111,414	-20.4%	Shares	Sole	2026-02-19
2025-09-30	$44,105,555	20,231,906	-0.5%	Shares	Sole	2025-11-14
2025-06-30	$25,821,844	20,332,161	+17.6%	Shares	Sole	2025-08-14
2025-03-31	$23,690,264	17,292,164	+3.5%	Shares	Sole	2025-05-14
2024-12-31	$41,942,970	16,710,347	-0.7%	Shares	Sole	2025-02-14
2024-09-30	$45,948,236	16,830,856	+128.2%	Shares	Sole	2024-11-14
2024-06-30	$17,403,487	7,374,359	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.